Evidence map›Paper›PMID 35575481›Full record

ArticleJournal of virology2022

Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function.

Isamu Tsuji, Fue Vang, David Dominguez, Lovkesh Karwal, Ankita Sanjali, Jill A Livengood, Edgar Davidson, Mallorie E Fouch, Benjamin J Doranz, Subash C Das and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Isamu TsujiVaccine Business Unit, Takeda Pharmaceutical Ltd., Cambridge, Massachusetts, USA.ORCID 0000-0002-4565-170X
Fue VangVaccine Business Unit, Takeda Pharmaceutical Ltd., Cambridge, Massachusetts, USA.
David DominguezVaccine Business Unit, Takeda Pharmaceutical Ltd., Cambridge, Massachusetts, USA.
Lovkesh KarwalVaccine Business Unit, Takeda Pharmaceutical Ltd., Cambridge, Massachusetts, USA.
Ankita SanjaliVaccine Business Unit, Takeda Pharmaceutical Ltd., Cambridge, Massachusetts, USA.
Jill A LivengoodVaccine Business Unit, Takeda Pharmaceutical Ltd., Cambridge, Massachusetts, USA.
Edgar DavidsonIntegral Molecular, Philadelphia, Pennsylvania, USA.
Mallorie E FouchIntegral Molecular, Philadelphia, Pennsylvania, USA.
Benjamin J DoranzIntegral Molecular, Philadelphia, Pennsylvania, USA.
Subash C DasVaccine Business Unit, Takeda Pharmaceutical Ltd., Cambridge, Massachusetts, USA.
Hansi J DeanVaccine Business Unit, Takeda Pharmaceutical Ltd., Cambridge, Massachusetts, USA.
Takeda (United States) · USIntegral Molecular (United States) · US

Funding

B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins 75N93019C00073 · NIAID · INTEGRAL MOLECULAR · PI DORANZ, BENJAMIN · 2019 to 2023
$7.5M
HHS | Biomedical Advanced Research and Development Authority (BARDA) HHSO100201600015CHHS | NIH | OSC | Common Fund (NIH Common Fund) HHSN 75N93019C00073NIAID NIH HHS 75N93019C00073
6 · The paper itself

Abstract

Zika virus (ZIKV) is a global public health concern due to its ability to cause congenital Zika syndrome and lack of approved vaccine, therapeutic, or other control measures. We discovered eight novel rabbit monoclonal antibodies (MAbs) that bind to distinct ZIKV envelope protein epitopes. The majority of the MAbs were ZIKV specific and targeted the lateral ridge of the envelope (E) protein domain III, while the MAb with the highest neutralizing activity recognized a putative quaternary epitope spanning E protein domains I and III. One of the non-neutralizing MAbs specifically recognized ZIKV precursor membrane protein (prM). Somatic hypermutation of immunoglobulin variable regions increases antibody affinity maturation and triggers antibody class switching. Negative correlations were observed between the somatic hypermutation rate of the immunoglobulin heavy-chain variable region and antibody binding parameters such as equilibrium dissociation constant, dissociation constant, and half-maximal effective concentration value of MAb binding to ZIKV virus-like particles. Complementarity-determining regions recognize the antigen epitopes and are scaffolded by canonical framework regions. Reversion of framework region amino acids to the rabbit germ line sequence decreased anti-ZIKV MAb binding activity of some MAbs. Thus, antibody affinity maturation, including somatic hypermutation and framework region mutations, contributed to the binding and function of these anti-ZIKV MAbs.

Indexed as

Antibodies, MonoclonalAntibodies, ViralSomatic Hypermutation, ImmunoglobulinZika VirusAnimalsAntibodies, NeutralizingComplementarity Determining RegionsEpitopesMutationRabbitsViral Envelope ProteinsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralComplementarity Determining RegionsEpitopesViral Envelope Proteinsaffinity maturationantibody functioncorrelation analysisframework region mutationneutralizing antibodiessomatic hypermutationZikaZika virus structure

Identifiers

PMID35575481
PMCPMC9175631
OpenAlexW4280519470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.